To be clear, this is a good decision:

Cotes banned Shkreli from the pharmaceutical industry for life and found him liable for $64.6 million in disgorgement. In January 2024, an appeals court upheld Cote's ruling.

Months later, Shkreli's lawyer filed a petition with the Supreme Court arguing that the ill-gotten profits from Daraprim's price hike went to corporate entities, not Shkreli personally, and that federal courts had issued conflicting rulings on disgorgement liabilities.

The Supreme Court has refused to let Shkreli off the hook.